论文部分内容阅读
目的:检测Notch1在卵巢上皮性肿瘤的表达,探讨其在卵巢癌的形成和转化过程中的表达特点及其与卵巢癌临床病理学参数的关系。方法:采用免疫组化法、逆转录聚合酶链反应(RT-PCR)法及Western blot法检测109例卵巢癌(其中65例为单侧卵巢癌)、65例单侧卵巢癌患者健侧卵巢(配对对照)及48例正常卵巢组织(正常对照)中Notch1的表达。结果:(1)卵巢癌中Notch1阳性表达率[95.4%(104/109)]显著高于配对对照组[7.7%(5/65)]和正常对照组[6.3%(3/48)](P<0.01),而后两组则无显著差异(P>0.05)。(2)卵巢癌中Notch1的表达与临床分期(FIGO)及病理分化程度有关(P<0.01),临床分期越高、分化程度越低,Notch1的表达越高;而与年龄、家族史、肿瘤位置、有无腹水、有无周围组织浸润、有无淋巴结转移、病理类型无关(P>0.05)。结论:Notch1在卵巢癌的发生发展过程中起着促癌基因作用,为卵巢癌的深入研究提供了一条新思路。
OBJECTIVE: To detect the expression of Notch1 in ovarian epithelial neoplasms, and to explore the expression of Notch1 in ovarian cancer during the formation and transformation and its relationship with the clinicopathological parameters of ovarian cancer. Methods: 109 cases of ovarian cancer (including 65 cases of unilateral ovarian cancer) were detected by immunohistochemistry, reverse transcription polymerase chain reaction (RT-PCR) and Western blot, and contralateral ovary in 65 cases of unilateral ovarian cancer (Paired control) and 48 cases of normal ovarian tissue (normal control) Notch1 expression. Results: (1) The positive expression rate of Notch1 in ovarian cancer was significantly higher than that in the matched control group [7.7% (5/65)] and the normal control group [95.4% (104/109)] P <0.01), but there was no significant difference between the latter two groups (P> 0.05). (2) The expression of Notch1 in ovarian cancer was correlated with clinical stage (FIGO) and pathological differentiation (P <0.01). The higher the clinical stage, the lower the differentiation was, the higher the Notch1 expression was. However, the correlation between Notch1 and age, family history, Location, with or without ascites, with or without surrounding tissue infiltration, with or without lymph node metastasis, pathological type has nothing to do (P> 0.05). Conclusion: Notch1 plays a role of oncogene in the development and progression of ovarian cancer, and provides a new idea for the further study of ovarian cancer.